{"filing":{"accession_number":"0001104659-26-109465","cik":"0000744218","ticker":"CLDX","company_name":"Celldex Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-22","report_date":"2026-09-22","primary_document":"tm2625892d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/744218/000110465926109465/tm2625892d1_8k.htm"},"events":[{"id":34170,"run_id":31440,"accession_number":"0001104659-26-109465","anchor_item_number":"8.01","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Celldex announced positive Phase 3 trial results for barzolvolimab in chronic spontaneous urticaria (CSU), meeting primary and all key secondary endpoints. While this is technically a clinical trial result rather than financial earnings, it is disclosed via press release in Item 8.01 and represents a material milestone that would significantly affect investor assessment of the company's pipeline value and regulatory prospects. The announcement of successful Phase 3 data supporting a planned 2027 BLA submission is a transformational event for a clinical-stage biopharmaceutical company.","company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","filing_date":"2026-09-22","form":"8-K","submitted_at":null,"items":[{"id":37834,"accession_number":"0001104659-26-109465","item_number":"8.01","item_title":"Other Events.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Celldex announced positive Phase 3 trial results for barzolvolimab in chronic spontaneous urticaria (CSU), meeting primary and all key secondary endpoints. While this is technically a clinical trial result rather than financial earnings, it is disclosed via press release in Item 8.01 and represents a material milestone that would significantly affect investor assessment of the company's pipeline value and regulatory prospects. The announcement of successful Phase 3 data supporting a planned 2027 BLA submission is a transformational event for a clinical-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T11:09:49.740700+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37834,"accession_number":"0001104659-26-109465","item_number":"8.01","item_title":"Other Events.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Celldex announced positive Phase 3 trial results for barzolvolimab in chronic spontaneous urticaria (CSU), meeting primary and all key secondary endpoints. While this is technically a clinical trial result rather than financial earnings, it is disclosed via press release in Item 8.01 and represents a material milestone that would significantly affect investor assessment of the company's pipeline value and regulatory prospects. The announcement of successful Phase 3 data supporting a planned 2027 BLA submission is a transformational event for a clinical-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T11:09:49.740700+00:00","company_name":"Celldex Therapeutics, Inc.","ticker":"CLDX","filing_date":"2026-09-22"}]}